Therapeutic and diagnostic target for cancer comprising dll3 binding reagents

Patent metadata

Field	Value
Publication number	US-2018201691-A1
Application number	US-201815914432-A
Country	US
Kind code	A1
Filing date	Mar 7, 2018
Priority date	Feb 12, 2013
Publication date	Jul 19, 2018
Grant date	—

Abstract

The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of cancer, such as lung cancer, pancreatic cancer and skin cancer, for monitoring the effectiveness of cancer, such as lung cancer, pancreatic cancer and skin cancer treatment, and for drug development.

First claim

1 . A method for the treatment or prophylaxis of cancer wherein DLL3 is expressed in said cancer, which comprises administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody which comprises a first binding domain for DLL3 and a second binding domain for CD3, wherein the bispecific antibody induces CD3-mediated effector cell activities against the cancer expressing DLL3.

2 . The method according to claim 1 , for the treatment or prophylaxis of a cancer selected from the group consisting of lung cancer, pancreatic cancer and skin.

3 . The method according to claim 1 , wherein the CD3-mediated effector cell activities comprise T-cell cytotoxicity or T cell clonal expansion.

4 . The method according to claim 1 , wherein the bispecific antibody induces apoptosis of cancer cells, kills or reduces the number of cancer stem cells and/or kills or reduces the number of circulating cancer cells.

5 . A method of detecting, diagnosing and/or screening for or monitoring the progression of a cancer wherein DLL3 is expressed in said cancer, or of monitoring the effect of a cancer drug or therapy wherein DLL3 is expressed in said cancer, in a subject which comprises detecting the presence or level of DLL3, or one or more fragments thereof, or the presence or level of nucleic acid encoding DLL3 or which comprises detecting a change in the level thereof in said subject.

6 . The method according to claim 5 which comprises detecting the presence of DLL3, or one or more fragments thereof, or the presence of nucleic acid encoding DLL3, in which either (a) the presence of an elevated level of DLL3 or said one or more fragments thereof or an elevated level of nucleic acid encoding DLL3 in the subject as compared with the level in a healthy subject, or (b) the presence of a detectable level of DLL3 or said one or more fragments thereof or a detectable level of nucleic acid encoding DLL3 in the subject as compared with a corresponding undetectable level in a healthy subject is indicative of the presence of cancer wherein DLL3 is expressed in said cancer, in said subject.

7 . A method of detecting, diagnosing and/or screening for or monitoring the progression of a cancer wherein DLL3 is expressed in said cancer, or of monitoring the effect of a cancer drug or therapy wherein DLL3 is expressed in said cancer, in a subject which comprises detecting the presence or level of antibodies capable of immunospecific binding to DLL3, or one or more fragments thereof.

8 . The method according to claim 7 , wherein the presence of DLL3, or one or more fragments thereof, or the presence of nucleic acid encoding DLL3, is detected by analysis of a biological sample obtained from the subject.

9 . The method according to claim 7 , wherein the presence of DLL3, or one or more fragments thereof, is detected using an affinity reagent which binds to DLL3.

10 . The method according to claim 9 , wherein the affinity reagent is an antibody or a functional fragment thereof or an antibody mimetic.

11 . The method according to claim 9 , wherein the affinity reagent contains or is conjugated to a detectable label.

12 . The method according to claim 7 , wherein the cancer is selected from the group consisting of lung cancer, pancreatic cancer and skin cancer.

13 . The method according to claim 7 , wherein the subject is a human.

14 . A method for identifying an agent for the treatment or prophylaxis of cancer wherein DLL3 is expressed in said cancer, wherein the method comprises (a) contacting DLL3, or one or more fragments thereof, with a candidate agent; and (b) determining whether the agent binds to DLL3, or one or more fragments thereof.

15 . The method according to claim 14 , further comprising the step of testing the ability of an agent which binds to DLL3, or one or more fragments thereof, to inhibit cancer wherein DLL3 is expressed in said cancer.

16 . The method according to claim 15 , wherein the agent modulates a physiological function of DLL3, inhibits ligand binding to DLL3 and/or inhibits a signal transduction pathway mediated by DLL3.

17 . The method according to claim 14 , wherein the cancer is selected from the group consisting of lung cancer, pancreatic cancer and skin cancer.

18 . A bispecific antibody which comprises a first binding domain specific for DLL3 and a second binding domain specific for CD3.

19 . The bispecific antibody of claim 18 , wherein antibody specifically binds to DLL3 expressed on the surface of a cancer cell and recruits human immune effector cells thereto.

20 . The bispecific antibody of claim 19 , wherein the cancer cell is a lung cancer cell, pancreatic cancer cell, or a skin cancer cell.

21 . The bispecific antibody of claim 18 , wherein the second binding domain specific for CD3 triggers a human immune effector cell activity selected from the group consisting of: T cell clonal expansion and T cell cytoxicity.

Assignees

• Boehringer Ingelheim Int

Inventors

• Hudson Lindsey Jane

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• G01N33/57525

  of the liver or pancreas · CPC title

• G01N33/5759

  involving compounds localised on the membrane of tumour or cancer cells · CPC title

• G01N33/5752

  of the lungs · CPC title

• G01N33/5751

  of the skin, e.g. melanoma · CPC title